Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4) X. Discriminants for tenth year treatment failure

Abstract

A search for prognostic discriminants of treatment failure in the tenth postmastectomy year was undertaken in 614 patients enrolled in protocol no. 4 of the National Surgical Adjuvant Project for Breast Cancers treated by radical mastectomy. Exploratory analyses of 38 pathologic and 6 clinical features disclosed 16 and 13 variables significantly related to nodal status and treatment failure, respectively. However, multivariate analyses with life tables adjusted or controlled for nodal status revealed that patients whose tumors measured <2 cm had a more favorable clinical course. All of the characteristics were also explored when patients were stratified according to numbers of nodal metastases, the most significant prognostic discriminant for disease-free survival in the tenth year. A germinal center predominance lymph node pattern and high histologic grade according to our conventional grading method were observed to adversely influence disease-free survival in patients with negative nodes. A strong trend in this manner was also observed with tumors 2 2 cm and types 3 and 5 scar cancers. Histologic grade and tumor size were significantly recognized as discriminatory in patients with 4+ nodes but no factors were significantly observed in the group of patients with 1 to 3 positive nodes. A possible explanation for this inconsistency is discussed. For the most part, these factors were also encountered by us previously at the 5-year postoperative period. Only the presence of 13+ nodal metastases and types 3 and 5 scar cancers and cancers without scar appeared to discriminate success or failure between the fifth and tenth year. It is therefore concluded that nodal category, germinal center predominance, histologic grade, and tumor size, in the contexts noted, represent strong prognostic discriminants exerting a rather constant influence on disease-free survival at least to the tenth postmastectomy period. The prognostic value of categorizing those patients with 4+ positive nodes into subgroups with 4 to 6, 7 to 12 and 13+ is reaffirmed. The actual disease-free survival of patients in the tenth year was not strikingly different from that observed previously by us at 5 years in this cohort.Cancer 53:712-723, 1984.N 197 1 the National Surgical Adjuvant Project for Breast I Cancers (NSABP) initiated a protocol to evaluate whether total mastectomy with or without postoperative

Expression of Bcl-2 in Breast Cancer: Correlation with Clinicopathological Characteristics and Survival

“…Tumour size -one of the most powerful predictors of tumour behaviour in breast cancer (9,17,54). Precise assessment of the tumour size is needed for adequate treatment.…”

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

“…Early reports of The Breast Cancer Linkage Consortium estimated a contralateral breast cancer cumulative risk of 50 -60% at age 70 years in BRCA1 or BRCA2 mutation carriers (Easton et al, 1995; The Breast Cancer Linkage Consortium, 1999). Later studies estimated even higher incidences of contralateral breast cancer within the first 5 years of follow-up after the primary breast cancer: 12 -33% among BRCA1 or BRCA2 mutation carriers (2.4 -6.5% per year) (Robson et al, 1998;Verhoog et al, 1998Verhoog et al, , 1999) as compared to a 0.4 -1% per year for breast cancer patients in general (Fisher et al, 1984).Owing to the elevated risks and fear of contralateral breast cancer, some women opt for contralateral prophylactic mastectomy (CPM). No studies to date exist on the efficacy of CPM in carriers of BRCA1 or BRCA2 mutations.…”

Risk communication in completed series of breast cancer genetic counseling visits

“…As opposed to carriers who have a strongly elevated risk of developing a contralateral cancer, 26 the incidence of contralateral cancer in breast cancer patients in general is only 0.4 -1% per year. 27 Counselees' inaccurate breast cancer risk perceptions may thus, at least partly, be explained by this risk not being communicated. Counselee-specific ovarian cancer risk was expressed to only half of the women.…”